ALK upgrades guidance after positive Q3 report

The allergy group now expects organic revenue growth of 11-12 percent compared to previous expectations of 10-12 percent.
Photo: ALK / PR
Photo: ALK / PR
by marketwire, translated by catherine brett and daniel pedersen

ALK has done better than antcipated on both its top and bottom lines, boosted by surpringsly strong sales of allergy drugs.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading